Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02422264 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02422264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02422264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
January 22, 2016
Completion date
March 7, 2018
Enrollment
601 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, diphtheria-tetanus-apertussis-hepatitis b-poliomyelitis-haemophilus influenzae type b vaccines, poliomyelitis, tetanus